Results 81 to 90 of about 14,435 (170)

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study

BMC Infectious Diseases
Background Two oral antivirals for treatment of COVID-19 are available in Australia, nirmatrelvir-ritonavir, which is recommended, and molnupiravir, which is approved for use when nirmatrelvir-ritonavir is contraindicated.
Laura J. Edwards, Anish Scaria, Allen C. Cheng, Janaki Amin, Elizabeth J. Robinson, Caroline Sumpton, Bette Liu   +6 more
doaj   +1 more source

An Intersectional Analysis of Social Deprivation and Patient Characteristics on Nirmatrelvir-Ritonavir for Treatment of COVID-19 in U.S. Primary Care Practices, 2021 to 2023

Journal of Primary Care & Community Health
Objective: Calculate rates of nirmatrelvir-ritonavir prescription and assess area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir for the treatment of COVID-19.
Esther E. Velásquez, Neil S. Kamdar, Nathaniel Hendrix, Xiaoyu Wang, Robert L. Phillips, David H. Rehkopf   +5 more
doaj   +1 more source

Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis

Tungs’ Medical Journal
Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly reduced the risk of coronavirus disease 2019 (COVID-19)-related ...
Chienhsiu Huang, Sufang Kuo, Lichen Lin
doaj   +1 more source

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir

Infectious Diseases and Therapy
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression.
Francesca Bai, Tomaso Beringheli, Virginia Vitaletti, Andrea Santoro, Francesco Molà, Alessandro Copes, Nicole Gemignani, Sofia Pettenuzzo, Roberto Castoldi, Benedetta Varisco, Riccardo Nardo, Lorenzo Brando Lundgren, Riccardo Ligresti, Matteo Sala, Lorenzo Albertini, Matteo Augello, Lorenzo Biasioli, Valeria Bono, Roberta Rovito, Teresa Bini, Sabrina Passarella, Nicola Vincenzo Orfeo, Antonella d’Arminio Monforte, Giulia Marchetti   +23 more
doaj   +1 more source

Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study:a target trial emulation study [PDF]

Background: Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the outcome of patients with mild-to-moderate COVID-19 symptoms.
Wong, Ian Chi Kei, Chan, Esther Wai Yin, Wan, Eric Yuk Fai, Yuen, Kwok Yung, Choi, Ming Hong, Hung, Ivan Fan Ngai, Chu, Wing Ming, Tam, Anthony Raymond   +7 more
core   +1 more source

Prognostic factors in the selection of antivirals for COVID-19 in high-risk outpatients: A retrospective cohort study

Therapeutic Advances in Infectious Disease
Background Early oral antiviral treatment reduced disease progression and hospitalisation in high-risk COVID-19 outpatients. In practice, prescribing decisions were influenced by clinical risk, drug interaction concerns, and physician judgment, even in ...
Puttirat Bunditwongpaisan, Natthakit Chavapradit   +1 more
doaj   +1 more source

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Infectious Disease Reports
Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound. We compared the incidence of symptom rebound in our remdesivir-treated cohort with rates reported
Kalpana Gupta, William J. O’Brien, Judith Strymish, Anna Chen, Katherine Linsenmeyer, Rebecca Madjarov, Michael E. Charness   +6 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug–drug interactions

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination that is authorized by the Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Dan Shen, Yinhua Gong, Yulan Qian, Jianguo Zhu, Jie Gao   +4 more
doaj   +1 more source

Nirmatrelvir-Ritonavir-Induced Pancreatitis: A Concern in the COVID Era. [PDF]

ACG Case Rep J
DeBroff J, Abraham J, Yoon BH, Cohen I.
europepmc   +1 more source

Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents. [PDF]

J Am Med Dir Assoc
Khan MA, Daiello LA, Berry SD, Harris DA, Mehta HB, Hsu YS, Leonard CE, McConeghy KW, Zullo AR.   +8 more
europepmc   +1 more source